Activeted-342650-2026

Discount Agreements for Ranibizumab

The Techniker Krankenkasse aims to establish discount agreements for the active ingredient Ranibizumab to achieve cost-effectiveness. This concerns the biologics sector for the year 2026.

View original source

CONTRACTING AUTHORITY

Name

Techniker Krankenkasse

City

Hamburg

Country

CLASSIFICATION

Procedure Type

Open Procedure

Contract Type

Supplies

Main CPV

33600000, Pharmaceutical products.

ADDITIONAL DETAILS

EU Funded

Yes

Suitable for SMEs

Electronic Submission

not-allowed

Legal Basis

32014L0024

DEADLINES & TIMELINE

Submission Deadline

06/30/202709:58 PM Uhr406 days remaining

(LOT-0001)

Published

05/18/2026

TENDER DOCUMENTS

406 days remaining

Similar Tenders

Explore CPV 33

Discount Agreements for Lipegfilgrastim

The Techniker Krankenkasse aims to enter into discount agreements for the active ingredient Lipegfilgrastim. The goal is to establish contracts with suitable pharmaceutical companies according to § 130a (8) SGB V.

Techniker Krankenkasse

·Hamburg

Deadline:June 30, 2028

Discount Agreements for Interferon beta-1b (Betaferon®)

The Techniker Krankenkasse aims to establish discount agreements for the medication Betaferon® with pharmaceutical companies. The goal is to reduce costs for Interferon beta-1b.

Techniker Krankenkasse

·Hamburg

Deadline:June 30, 2028

Discount Agreements for Epoetin theta

The Techniker Krankenkasse aims to establish discount agreements for the active ingredient Epoetin theta to ensure supply and optimize costs.

Techniker Krankenkasse

·Hamburg

Deadline:June 30, 2028